Our first AI discovered candidate enters laboratory validation
The first candidate designed end to end by Discovery AI has entered laboratory validation, completing the full discovery to laboratory workflow for the first time.
Announcements, milestones and insights from across the Syngenis platform and laboratories.
A simple, filterable feed of company news and longer perspective pieces. Each article has its own indexable URL, a clear date, an author, a category and a share image.

Milestones, partnerships and facility updates.

Perspectives on RNA medicine, Discovery AI and sovereign capability.
The first candidate designed end to end by Discovery AI has entered laboratory validation, completing the full discovery to laboratory workflow for the first time.
Human grade DNA and RNA manufacturing is concentrated in a small number of countries. Syngenis is bringing that capability onshore, with Australia's only commercial RNA facility.
For a century, medicine was built from chemistry. RNA and DNA medicines work differently, reading, understanding and responding to disease at the molecular level.
Get milestones, announcements and perspectives from Syngenis as they are published.